Medline Inc. IPO - What You Need to Know

Thinking about buying into the Medline IPO? It is a massive name in the medical world. Now that we have official filings, we can see how they operate and what you are actually buying. Here is the breakdown in plain English.

1. What does this company do?

Think of Medline as the "Amazon of hospitals." They are the largest private manufacturer and distributor of medical supplies in the U.S. They operate through two main arms:

• Medline Brand: They make their own products, from surgical kits and gloves to wound care and diagnostic tools. They offer about 190,000 items and hold over 2,300 patents to protect their designs.
• Supply Chain Solutions: They act as a giant logistics machine. They distribute 145,000 products from over 1,300 other brands. This makes them a "one-stop shop" for hospitals, nursing homes, and surgery centers.

2. Why do they win?

Medline uses a "Prime Vendor" model, signing long-term contracts to be a hospital’s main supplier. Their success relies on:

• The Flywheel: Once they win a contract, they use their network to push Medline-branded products. These products are much more profitable than reselling goods from other companies.
• Built-in Demand: U.S. healthcare spending has grown every year for 60 years. Even in a shaky economy, medical care remains essential, which protects the business from market swings.
• Logistics Power: They own over 2,100 "MedTrans" trucks and 60 distribution centers. This lets them control their own deliveries and avoid shipping delays.

3. The Financial Snapshot

In 2025, Medline generated $28.4 billion in total revenue and $1.2 billion in profit. While distribution brings in the most sales, their "Medline Brand" products are the real profit engine. They generate about 80% of the company's segment profit. This manufacturing capability drives their cash flow.

4. The IPO Details

Medline hit the Nasdaq under the ticker “MDLN” at $37.00 per share.

Crucial detail: This is a "secondary offering." Medline is not issuing new shares to raise cash for the company. The company receives no money from this sale. The founding Mills family and private equity firms (Blackstone, Carlyle, and Hellman & Friedman) are selling their existing shares to cash out.

5. What are the main risks?

• The "Exit" Factor: The current owners are the ones selling. While they keep voting control, they are reducing their stake. Their interests might not always align with yours.
• Complex Structure: Medline uses an "UP-C" structure. This is a tax-efficient setup that creates different classes of units for insiders. These units can be swapped for common stock later. This could lead to more shares being issued, which would reduce your ownership percentage.
• Debt and Competition: The company carries a significant amount of debt from past growth and payouts. High interest costs can limit cash flow. They also face tough competition and strict FDA rules that could hurt their pricing power.

6. A Final Word of Advice

IPOs are often volatile, and the $37.00 price was just the starting point.

Pro-tip: Since this is a secondary offering, you aren't funding the company's future growth; you are buying an existing stake from the people who built the business. Before you jump in, make sure your plan accounts for the company’s debt levels and the potential for your ownership percentage to be diluted if insiders swap their units for more common stock later on.

Disclaimer: I am an AI, not a financial advisor. This guide is for educational purposes only and does not constitute financial advice. Always do your own research or consult with a professional before investing.